IHC - Microsatellite Instability for Colorectal Carcinoma MLH-1 Test, Price, Normal Range | Sprint Diagnostics Hyderabad

This test is important because it helps in determining the prognosis and guiding the treatment decisions for patients with colorectal cancer.

No special preparation is needed as the sample is usually taken during a biopsy or surgery.

Absence or reduced expression of the MLH1 protein can indicate the presence of microsatellite instability, which has implications on the prognosis and treatment options.

No, there are other tests like PCR-based tests for MSI, and often testing for multiple mismatch repair proteins is done concurrently.

This test is usually performed once, typically when diagnosing colorectal cancer. However, your healthcare provider will guide you based on your individual case.

Genetic mutations, methylation of the MLH1 gene, and certain environmental factors can affect the levels of MLH1 protein.

If the MLH1 protein is absent, you should consult with your oncologist who will guide you on the next steps, which may include further genetic testing and personalized treatment options.

In a healthy tissue, MLH1 protein is usually present. Absence or significantly reduced expression of MLH1 protein in tumor tissue is indicative of microsatellite instability and can suggest Lynch syndrome, a form of hereditary colorectal cancer.

As the test is performed on a tissue sample, there are no direct side effects. However, the tissue sample collection through a biopsy or surgery may have associated risks.

MLH1 protein is crucial for DNA mismatch repair - a process that corrects errors made during DNA replication. This function helps maintain the stability of the cell's genetic material. If MLH1 protein is absent or not functioning properly, these errors may not be corrected, leading to genetic mutations that can cause cancer.

The levels of MLH1 protein are primarily determined by genetic factors. However, certain environmental exposures like smoking or a diet low in folate have been associated with MLH1 gene silencing, which could potentially impact the protein levels.

Yes. While it's most commonly used in the context of colorectal cancer, IHC - MLH1 can also be useful in the diagnosis of other cancers, such as endometrial cancer, where MLH1 protein loss is also seen.

While IHC - MLH1 test provides valuable information, it's typically used in conjunction with other tests for a more comprehensive assessment of microsatellite instability. This can include testing for other mismatch repair proteins and molecular tests like PCR for microsatellite instability.

Typically, IHC - MLH1 is not used for monitoring treatment progress. However, changes in MLH1 expression could potentially be studied in research settings to understand the impact of certain treatments on microsatellite instability.

Abnormal results, specifically reduced or absent expression of MLH1 protein, may suggest a diagnosis of microsatellite instability or Lynch syndrome. If this happens, your doctor will discuss the results with you and guide you on the next steps, which could include further testing or consultations with a genetic counselor.

The IHC - MLH1 test is a reliable and well-established method for detecting the presence of MLH1 protein. However, the results should be interpreted in conjunction with other clinical and laboratory findings.

Yes, molecular tests such as PCR for microsatellite instability or genetic testing for Lynch syndrome may be performed if the results of the IHC - MLH1 test are inconclusive or if further information is required.

If the IHC - MLH1 test shows absent or reduced MLH1 protein expression, it could suggest a hereditary form of colorectal cancer known as Lynch syndrome. However, further genetic testing is usually required to confirm this diagnosis.

The results of the IHC - MLH1 test are typically interpreted by a pathologist who specializes in cancer diagnosis. The pathologist's report will then be used by your treating physician to understand the disease better and to decide the next course of action.

The importance of the IHC - MLH1 test in the diagnosis and management of colorectal cancer cannot be overstated. By assessing the presence or absence of MLH1 protein, this test offers insights into the likelihood of a patient having microsatellite instability or Lynch syndrome, both of which have significant implications for treatment and prognosis. While the test itself may not offer a complete picture of the patient's condition, it is an essential component of a comprehensive diagnostic process. If you have been recommended this test, rest assured that it will contribute valuable information to guide your healthcare journey.